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Abstract While it was thought that most of cerebral crea-
tine is of peripheral origin, AGAT and GAMT are well
expressed in CNS where brain cells synthesize creatine.
While the creatine transporter SLC6A8 is expressed by
microcapillary endothelial cells (MCEC) at blood-brain bar-
rier (BBB), it is absent from their surrounding astrocytes.
This raised the concept that BBB has a limited permeability
for peripheral creatine, and that the brain supplies a part of
its creatine by endogenous synthesis. This review brings
together the latest data on creatine and guanidinoacetate
transport through BBB and blood-CSF barrier (BCSFB) with
the clinical evidence of AGAT-, GAMT- and SLC6A8-
deficient patients, in order to delineate a clearer view on the
roles of BBB and BCSFB in the transport of creatine and
guanidinoacetate between periphery and CNS, and on brain
synthesis and transport of creatine. It shows that in physiolog-
ical conditions, creatine is taken up by CNS from periphery
through SLC6A8 at BBB, but in limited amounts, and that
CNS also needs its own creatine synthesis. No uptake of
guanidinoacetate from periphery occurs at BBB except under
GAMT deficiency, but a net exit of guanidinoacetate seems to
occur from CSF to blood at BCSFB, predominantly through
the taurine transporter TauT.
Introduction
In the brain as in most tissues, the creatine (Cr) / phospho-
creatine (PCr) / creatine kinase (CK) system plays essential
roles to maintain the high energy levels necessary for CNS
development and functions, through regeneration and buff-
ering of ATP levels (Brosnan and Brosnan 2007; Wyss and
Kaddurah-Daouk 2000). Recent works suggest that Cr in
CNS may also act as true neurotransmitter and one of the
main CNS osmolytes (Almeida et al. 2006; Bothwell et al.
2002). In mammals, half of Cr is obtained from diet, the
other half being synthesized endogenously by a two-step
mechanism involving arginine:glycine amidinotransferase
(AGAT; EC 2.1.4.1; gene: GATM) and guanidinoacetate
methyltransferase (GAMT; EC 2.1.1.2; gene: GAMT). Cr
is distributed by blood to tissues and taken up by cells
through a specific Cr transporter, SLC6A8 (gene: SLC6A8),
also called CT1, CRT1, CRTR, CTR or CreaT (Wyss and
Kaddurah-Daouk 2000).
The brain is protected from variations in the blood milieu
by different barriers which tightly regulate exchanges be-
tween periphery and CNS, the two most important being
blood-brain barrier (BBB) and blood-cerebrospinal fluid
barrier (BCSFB). BBB represents, by many orders of magni-
tude, the largest barrier between periphery and the brain
(Fig. 1). It consists of non-fenestrated microcapillary endothe-
lial cells (MCEC) connected together by tight and adherent
junctions that prevent paracellular diffusion of molecules be-
tween blood and CNS parenchyma (Engelhardt and Sorokin
2009). Specifically expressed transporters on luminal and
abluminal sides of MCEC, together with a very limited pino-
cytosis, allow the tight regulation of exchanges through BBB.
Moreover, these exchanges are also strongly regulated by (i)
cells adjacent to the abluminal side of MCEC (namely peri-
cytes which cover about 32% of the microcapillary surface;
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and astrocytic feet which cover more than 98% of the surface
made by MCEC and pericytes; Cardoso et al. 2010; Neuwelt
et al. 2011) and (ii) a specific extracellular matrix which
sheathes MCEC, pericytes and astrocytic feet and limits the
diffusion of molecules between MCEC and CNS (Dityatev et
al. 2010). BCSFB (Fig. 2), located in lateral, third and fourth
ventricles, is made by unique apical tight junctions between
the choroid plexus epithelial cells (CPEC), which are respon-
sible of the secretion of CSF and also express specific trans-
porters allowing regulated exchanges between CSF and blood
(Engelhardt and Sorokin 2009; Spector 2010; Wolburg and
Paulus 2010).
While it was thought that most, if not all, cerebral Cr is of
peripheral origin, AGAT and GAMT are well expressed in
CNS where brain cells can synthesize their own Cr (Béard
and Braissant 2010; Braissant et al. 2008). In brain paren-
chyma, SLC6A8 is expressed by neurons and oligodendro-
cytes. However, while SLC6A8 is also expressed by MCEC
at BBB, allowing CNS to import Cr from periphery, it is
absent from astrocytes, particularly from their feet lining
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Fig. 1 Transport of creatine (Cr) and guanidinoacetate (GAA) at the
blood-brain barrier (BBB). a: in normal conditions; b: under GAMT
deficiency. In normal conditions (a), Cr is taken up by CNS from
periphery through SLC6A8 expressed on MCEC at BBB, but in
limited amounts in reason of the absence of SLC6A8 in the surround-
ing astrocytes and the difficult diffusion of Cr through ECM surround-
ing BBB. Therefore, the brain needs its own synthetic pathway to
ensure sufficient levels of Cr, and do so by expressing AGAT and
GAMT. No uptake of GAA from periphery occurs at BBB, except
under GAMT deficiency (b) and maybe also SLC6A8 deficiency. Arg:
arginine; AGAT: arginine:glycine amidinotransferase; Cr: creatine;
ECM: extracellular matrix; GAA: guanidinoacetate; GAMT: guanidi-
noacetate methyltransferase; Gly: glycine; MCEC: microcapillary en-
dothelial cells (BBB); P: pericyte; SLC6A8: Cr transporter
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Fig. 2 Transport of creatine (Cr) and guanidinoacetate (GAA) at the
blood-cerebrospinal fluid barrier (BCSFB). a: in normal conditions; b:
under GAMT deficiency. In normal conditions (a), CPEC are able to
take up Cr both from blood and CSF; a net exit of GAA seems to occur
from CSF to blood at BCSFB under physiological conditions, predom-
inantly through TauT. This exit of GAA from CSF to blood may be
increased under GAMT deficiency (b), and uses both TauT and
SLC6A8. CPEC: choroid plexus epithelial cells (BCSFB); Cr: creatine;
CSF: cerebrospinal fluid; Ep: ependymal epithelium; GAA: guanidi-
noacetate; SLC6A8: Cr transporter; TauT: taurine transporter
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BBB (Braissant et al. 2001b; Ohtsuki et al. 2002; Tachikawa
et al. 2004). This raised the concept that BBB has a limited
permeability for peripheral Cr, and that the brain supplies a
part of its Cr by endogenous synthesis (Braissant et al.
2001b; Braissant et al. 2011; Braissant and Henry 2008).
However, despite indeed a limited efficiency of brain Cr
uptake from periphery, shown in vivo both in rodents (Ohtsuki
et al. 2002; Perasso et al. 2003) as well as in AGAT- and
GAMT-deficient patients (AGAT: OMIM #612718; GAMT:
OMIM #612736) treated by Cr (Schulze 2005), Cr (and the
intermediate guanidinoacetate, GAA) do cross BBB and
BCSFB (Tachikawa and Hosoya 2011).
This review brings together (i) the latest experimental
data on the transport of Cr and GAA through BBB and
BCSFB with (ii) the clinical evidence shown in the patients
deficient for AGAT, GAMT and SLC6A8 (SLC6A8: OMIM
#300352), in order to delineate a clearer view of the roles of
BBB and BCSFB in the transport of Cr and GAA between
periphery and CNS, and on the synthesis and transport of Cr
within the brain, both in the mature brain and during
development.
Cr and GAA through BBB and BCSFB, and within CNS
It is thought that most of peripheral synthesis of Cr occurs
through AGAT in kidney and GAMT in liver (Brosnan and
Brosnan 2007), implying the transport of the intermediate
GAA through blood circulation. Cr is also synthesized in the
mammalian brain (Béard and Braissant 2010; Pisano et al.
1963). The recent knowledge of how AGAT and GAMT, as
well as the Cr transporter SLC6A8, are expressed and active
at BBB and BCSFB, as well as within CNS, sheds light on
the respective importance of Cr synthesis within the brain
versus Cr and GAA uptake from periphery or release from
CNS.
AGAT and GAMT are well expressed in the brain, where
they are found, in all CNS structures, in every main cell
types (neurons, astrocytes and oligodendrocytes; Braissant
et al. 2001b; Nakashima et al. 2005; Schmidt et al. 2004;
Tachikawa et al. 2004). We have shown recently that
AGAT and GAMT, in most regions of the rat brain, appear
expressed in a dissociated way, being rarely co-expressed
within the same cell (Braissant et al. 2010). AGAT, but not
GAMT, is expressed by MCEC at BBB (Braissant et al.
2001b; Tachikawa et al. 2004), while AGAT and GAMT are
expressed by choroid plexus at BCSFB (Braissant et al.
2001b).
SLC6A8 is also expressed throughout the mammalian
brain in neurons and oligodendrocytes (Braissant et al.
2001b; Happe and Murrin 1995; Mak et al. 2009; Schloss
et al. 1994; Tachikawa et al. 2008). However, in physiological
conditions and in contrast to AGAT and GAMT, it cannot be
detected in astrocytes (Acosta et al. 2005; Braissant et al.
2001b; Nakashima et al. 2004), except for very few in cere-
bellum (Mak et al. 2009). In contrast to its absence from the
astrocytic feet lining microcapillaries, SLC6A8 is present in
MCEC making BBB, where it is expressed at both luminal
and abluminal sides ofMCEC (Braissant et al. 2001b; Ohtsuki
et al. 2002; Tachikawa et al. 2004) (Fig. 1). At BCSFB,
SLC6A8 is mainly expressed at the brush-border membrane
of choroid plexus epithelial cells, and to a lesser extent on their
basal membrane (Braissant et al. 2001b; Tachikawa et al.
2008) (Fig. 2).
Peripheral Cr can enter the brain. In vivo experiments in
mouse and rat have demonstrated that CNS can take up Cr
from the blood against its concentration gradient, at least to
some extent (Ohtsuki et al. 2002; Perasso et al. 2003).
However, it has been known for a very long time that this
passage of peripheral Cr into the brain is limited. Oral
treatment of normal rats with Cr does not increase their
CNS Cr content (Chanutin 1927), while oral administration
of Cr in healthy human volunteers with about 60 times the
daily needs in Cr only leads to a very modest 5% to 10%
increase in their brain total Cr (Cr+PCr) after one month of
treatment (Dechent et al. 1999). The restricted crossing of
peripheral Cr into CNS is also illustrated in Cr orally-treated
AGAT- and GAMT-deficient patients who, despite the high
doses of Cr used (usually 0.35-2.00 g/kg/day; 20-120 times
the normal needs in Cr), replenish their cerebral Cr only
slowly, Cr restoration taking months and remaining in most
cases only partial (Battini et al. 2002; Ganesan et al. 1997;
Item et al. 2001; Schulze 2005; Schulze et al. 1998; Stöckler
et al. 1996). GAMT-/- KO mice treated with the high dose of
2 g/kg/day of Cr normalize their brain Cr after 16 to 35 days
of treatment, depending on CNS region (Kan et al. 2007).
At BBB (Fig. 1), in vivo analysis in mouse has shown
that the carrier-mediated uptake of Cr from blood to brain
through BBB has an influx transport clearance of 1.6 μL/
(min*g brain) (Ohtsuki et al. 2002), about six times greater
than that of sucrose, for which BBB is not permeable, but
about 50 times smaller than that of glucose (Hasselbalch et
al. 1995). Using TM-BBB4 cells (conditionnally immortal-
ized mouse brain capillary endothelial cells) as in vitro
model for BBB, Ohtsuki et al. showed that Cr is taken up
by TM-BBB4 cells by a Na+/Cl--dependent carrier having a
Km of 16 μM and being strongly inhibited by guanidino-
propionate and GAA, presenting thus characteristics of
SLC6A8 which is expressed at BBB in MCEC (Braissant
et al. 2001b; Ohtsuki et al. 2002). SLC6A8 can also mediate
the transport of GAA, however with a Km value ten times
greater than for Cr (Tachikawa and Hosoya 2011). There-
fore, as GAA levels in blood (1-3.5 μM) are 2-50 times
lower than levels of Cr (6-50 μM), it is unlikely that in
physiological conditions GAA is taken up from blood by
MCEC (Tachikawa et al. 2009). No elimination of GAA
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from brain parenchyma through BBB could be observed
(Tachikawa et al. 2009).
At BCSFB (Fig. 2), in vivo analysis in mouse has also
revealed a carrier-mediated uptake of Cr from blood to CSF
through CPEC, with an influx transport clearance of 3.6 μL/
(min*ml CSF) (Tachikawa et al. 2008). Tachikawa et al.
also showed that GAA can be taken up by TR-CSFB cells
(immortalized rat choroid plexus cells) and isolated rat
choroid plexus used as in vitro model for BCSFB. This
uptake of GAA by BCSFB cells appears to be mediated
through at least three different mechanisms, two main
Na+/Cl--dependent carrier activities having the characteristics
of SLC6A8 and of the taurine transporter TauT, and a much
smaller transmembrane diffusion (Tachikawa et al. 2008).
There appears to be a net efflux of GAA through BCSFB,
the elimination clearance of CSF to blood through BCSFB
(3.97 μL/min per rat) being about 33 times higher than the
blood-to-CSF influx clearance of GAA through BCSFB
(0.12 μL/min per rat) (Tachikawa and Hosoya 2011). Efflux
of GAA from CSF to blood may thus occur through both
SLC6A8 and TauT. However, the much higher concentration
of Cr (17-90 μM) than GAA (0.015-0.114 μM) in CSF most
probably considerably limits the efflux of GAA from CSF
through SLC6A8 (Tachikawa et al. 2008).
Cr and GAA at BBB and BCSFB : What can be learned
from Cr deficiency syndromes?
CNS is the main organ affected in patients suffering from the
Cr deficiency syndromes, inborn errors of Cr biosynthesis and
transport caused bymutations in theGATM,GAMTor SLC6A8
genes (Item et al. 2001; Salomons et al. 2001; Stöckler et al.
1994). Cr-deficient patients present neurological symptoms in
infancy (Battini et al. 2002; DeGrauw et al. 2002; Schulze et al.
1997). In particular, intellectual disability and delays in speech
acquisition can be observed (AGAT, GAMT and SLC6A8
deficiencies), as well as intractable epilepsy (GAMT and
SLC6A8 deficiencies), autism, automutilating behavior, extra-
pyramidal syndrome and hypotonia (GAMT deficiency)
(Stöckler et al. 2007). With the exception of SLC6A8-
deficient heterozygous females where brain Cr deficiency is
often partial (Cecil et al. 2003; Valayannopoulos et al. 2011;
van de Kamp et al. 2011a), the common phenotype of these
three primary Cr deficiencies is the virtual absence of the Cr
peak measured by magnetic resonance spectroscopy (MRS) in
cortex and basal ganglia (Stöckler et al. 2007).
AGAT- and GAMT-deficient patients can be treated by
oral supplementation of Cr. While this strongly improves
their neurological status and CNS development, high doses
of Cr must be used (usually 0.35-2.0 g/kg/day; 20-120 times
the normal needs in Cr) while replenishment of cerebral Cr
takes months and only results in partial restoration of
cerebral Cr pools (Battini et al. 2002; Ganesan et al. 1997;
Item et al. 2001; Schulze et al. 1998; Stöckler et al. 1996).
One exception to these high doses of Cr used to treat Cr-
deficient patients is a presymptomatic AGAT patient who
received 0.1 g/kg/day of Cr since the age of 4 months
(Battini et al. 2006). This interesting case is described in
more detail in the following chapter on Cr in immature CNS.
A very high dose of creatine (2.0 g/kg/day) was also used in
GAMT-/- KO mice to analyze their CNS replenishment in Cr
(Kan et al. 2007). All these data suggest that BBB has a
limited permeability for Cr. Despite improvement of clinical
outcome by Cr supplementation, most AGAT- and GAMT-
deficient patients remain with CNS developmental problems.
Oral supplementation of Cr is inefficient in replenishing brain
Cr in SLC6A8-deficient patients, who remain with intellectual
disability, severe speech impairment and progressive brain
atrophy (Bizzi et al. 2002; Cecil et al. 2001; DeGrauw et al.
2002; Póo-Argüelles et al. 2006). This suggests that Cr cannot
enter CNS from periphery by other means than SLC6A8.
Attempts to treat SLC6A8-deficient patients with arginine
and glycine as precursors of Cr gave somemodest encouraging
results in two SLC6A8-deficient patients (Chilosi et al. 2008;
Wilcken et al. 2008), while it failed to improve the neurological
status of many others (Fons et al. 2008; Valayannopoulos et al.
2011; van de Kamp et al. 2011b). BBB and its surrounding
astrocytes efficiently express cationic amino acid transporters
(CATs 1 and 2B) allowing the import of arginine from periph-
ery to the blood (Braissant et al. 2001a; Braissant et al. 1999).
Altogether, data on the treatment of Cr-deficient patients indi-
cate that Cr is taken up in limited amounts by CNS from
periphery, and that this modest transport of Cr through BBB
most probably exclusively occurs through SLC6A8 (Béard
and Braissant 2010; Braissant and Henry 2008) (Fig. 1).
Despite the almost complete lack of Cr observed by
MRS, Cr remains present within the brain of Cr-deficient
patients (Braissant and Henry 2008). In SLC6A8 deficiency,
Cr CSF levels do not differ from age-matched controls
(Cecil et al. 2001; DeGrauw et al. 2002; Salomons et al.
2001), while total Cr estimated by MRS has been measured
to 1.6 mM in a male patient (21% to 35% of controls;
normal range 5.5-7.5 mM; Dezortova et al. 2008). In AGAT
deficiency, total Cr levels in cortical gray matter are de-
creased to 12% of age-matched controls (Battini et al.
2002). In GAMT deficiency, CSF Cr levels are strongly
decreased (<2 μM; normal range: 17-90 μM) (Ensenauer
et al. 2004; Schulze et al. 1997; Schulze et al. 2003), while
in cortical gray matter total Cr was measured in the 0.2-
1.5 mM range (normal range: 5.5-7.5 mM) (Mancini et al.
2005; Stöckler et al. 1994; Dezortova et al. 2008). As the
entry of Cr from periphery to CNS appears to exclusively
occur through SLC6A8 at BBB (Tachikawa et al. 2009), the
presence of normal levels of Cr in CSF of SLC6A8-deficient
patients and Cr levels in brain parenchyma between 21%
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and 29% of controls must be due to an active CNS endog-
enous synthesis pathway for Cr (Dezortova et al. 2008;
Béard and Braissant 2010; Braissant et al. 2010). As this
endogenous brain Cr synthesis pathway is invalidated in
AGAT and GAMT deficiencies, the low levels of Cr found
in the brain of their respective patients must enter the brain
at BBB, through SLC6A8 expressed in MCEC, with the
limited efficacy described above (Braissant and Henry 2008;
Tachikawa and Hosoya 2011).
GAA accumulation in body fluids is characteristic of
GAMT deficiency, where GAA toxicity is responsible for its
more complex and specific phenotype. GAA CSF levels in
GAMT-deficient patients are 60-1000× higher than in age-
matched controls (6.6-15.3 μM versus 0.015-0.114 μM),
while GAA was estimated at 3.6 mM within cortical gray
matter (normal range: 1.6 mM). GAA can also accumulate
in the brain of SLC6A8-deficient patients (Sijens et al. 2005).
It was shown that both BBB endothelial cells (Tachikawa et al.
2009) and CNS parenchymal cells (Braissant et al. 2010;
Tachikawa et al. 2008) are able to take up GAA by SLC6A8.
As the Km value of SLC6A8 for GAA (269-412 μM) appears
ten times higher than that for Cr (29-46 μM) (Tachikawa et al.
2008; Tachikawa and Hosoya 2011), the entry of GAA into
CNS in normal conditions must be inhibited by blood Cr
levels (Fig. 1a). Under GAMT deficiency however (Fig. 1b),
this entry might be facilitated, blood GAA levels becoming
higher than Cr levels (Almeida et al. 2004), therefore contrib-
uting to GAA accumulation into the GAMT-deficient brain.
Endogenous brain AGAT activity must also contribute to
GAA accumulation in the CNS of GAMT-deficient patients
(Braissant and Henry 2008). Similarly, GAA accumulating in
the brain of some SLC6A8-deficient patients (Sijens et al.
2005) is most probably essentially due to brain AGATactivity
and the impossibility for GAA to enter GAMT-expressing
cells as functional SLC6A8 is lacking (Béard and Braissant
2010; Braissant et al. 2010), and to the lack of SLC6A8-
mediated GAA efflux at BCSFB (Tachikawa and Hosoya
2011). Normal levels of GAA in the plasma of SLC6A8-
deficient patients most probably makes negligible the contri-
bution of GAA passive diffusion at BBB (Tachikawa et al.
2009) for CNS GAA accumulation in SLC6A8-deficiency.
SLC6A8 as well as TauT expressed in the brush-border mem-
brane of choroid plexus at BCSFB may contribute, in GAMT
and maybe SLC6A8 deficiencies, to some elimination of
GAA from CSF (Tachikawa et al. 2008; Tachikawa et al.
2009; Tachikawa and Hosoya 2011) (Fig. 2b).
Models of transport of Cr and GAA at BBB and BCSFB
Taken together, experimental data on (i) SLC6A8 expres-
sion, (ii) functional analysis of Cr and GAA transport and
(iii) activity and characterization of SLC6A8 and TauT at
BBB and BCSFB, as well as (iv) the brain characteristics of
Cr-deficient patients and the way they respond to Cr treat-
ment, suggest the following models for Cr and GAA transport
through BBB and BCSFB (Figs. 1 and 2).
At BBB, SLC6A8 is expressed on both luminal and
abluminal sides of MCEC (Fig. 1). In physiological condi-
tions (Fig. 1a), a net entry of Cr from periphery to CNS
occurs, most probably through SLC6A8 only. This uptake
of peripheral Cr by the brain is limited, due to the absence of
SLC6A8 in the astrocytic feet covering most of BBB and
the weak diffusion of Cr through the surrounding ECM.
CNS can ensure its own Cr synthesis thanks to endogenous
expression of AGAT and GAMT, which appear dissociated
in most regions of the brain, thus necessitating the transfer
of GAA from AGAT- to GAMT-expressing cells through
SLC6A8 for completing Cr synthetic pathway. No transfer
of GAA occurs through BBB in normal conditions, due to
the favorable competition of Cr over GAA for SLC6A8.
Under GAMT deficiency however, the competition for
SLC6A8 is reversed in favor of GAA, which may cross
BBB from periphery and contributes, together with the
endogenous brain AGAT activity, to GAA accumulation in
the brain of GAMT-deficient patients (Fig. 1b). So far,
nothing is known on the use of Cr by pericytes. Equally,
the role of SLC6A8 on the abluminal side of MCEC, as well
as the way Cr and GAA can leave the cells, are not under-
stood (Fig. 1a).
At BCSFB, SLC6A8 is predominantly expressed on the
brush-border apical side of CPEC, as well as weaker on their
basal side (Fig. 2). In physiological conditions (Fig. 2a), it is
not clear whether a net entry of Cr from periphery, or exit of
Cr from CSF, occur at BCSFB. There appears to be a net
exit of GAA from CSF to blood, predominantly through
TauT. This net exit of GAA from CSF to blood through
BCSFB may be stronger under GAMT deficiency (Fig. 2b),
and may occur both through TauT and SLC6A8 (favorable
competition of GAA over Cr). The exchanges of Cr and
GAA between CSF and brain parenchyma, and particularly
its extracellular fluid, are not clearly understood so far.
Brain Cr : Different roles for BCSFB and BBB
between immature and mature CNS
As proposed above, adult (or mature) CNS might privilege
Cr endogenous synthesis versus uptake from periphery. The
fetal and perinatal (or immature) brain probably behaves
differently. In mammals, the fetal needs in Cr are partly
supported by transport of Cr from mother to fetus (Davis
et al. 1978; Ireland et al. 2008; Ireland et al. 2011). On the
other side, AGAT, GAMT and SLC6A8 are well expressed
during embryogenesis, including in CNS (Braissant et al.
2005; Ireland et al. 2009; Wang et al. 2007). However, the
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low level of GAMT in early stages suggests that, in contrast
to adult brain, fetal and perinatal CNS may predominantly
depend on Cr supply from periphery (Braissant et al. 2007).
BCSFB develops much earlier than BBB, and is thus the
first structure responsible for exchanges between periphery
and CNS during development (Fig. 3). The Cr supply to
CNS from periphery is probably made possible by the much
higher expression of SLC6A8 in CPEC (BCSFB) during
development (Braissant et al. 2005) than in the mature brain
(Braissant et al. 2001b; Tachikawa et al. 2008), as well as by
the very high expression of SLC6A8 in fetal ependymal
cells and periventricular zone, as shown in rat (Braissant et
al. 2005) and human embryos (O.Braissant and H.R.
Widmer, unpublished results) (Fig. 3). In contrast at BBB,
SLC6A8 is not detectable in the first stages of MCEC
development (Braissant et al. 2005), while it is expressed
in mature MCEC (Braissant et al. 2001b; Ohtsuki et al.
2002) (Fig. 3).
The better capacity of immature CNS to take up Cr from
periphery is illustrated in two recent studies that showed that
the pre-symptomatic treatment of AGAT and GAMT defi-
ciencies appears to completely prevent the phenotypic ex-
pression of these diseases (Schulze and Battini 2007). An
AGAT-deficient boy, brother of two already affected AGAT-
deficient sisters, was diagnosed at birth with the same
homozygous mutation as his sisters, and treated orally since
the age of 4 months with Cr monohydrate (0.1 g/kg/day;
Battini et al. 2006). Similarly, a GAMT-deficient girl, sister
of an already affected GAMT-deficient brother, was diag-
nosed at birth with the same mutations as her brother, and
treated orally since the age of 22 days with Cr monohydrate
(0.4 g/kg/day; Schulze et al. 2006). Both patients, over a
follow-up of more than 5 years, did not develop the charac-
teristic CNS phenotypic expression of AGAT and GAMT
deficiencies (Schulze and Battini 2007). These two cases
suggest that Cr plays an essential role in the development of
CNS higher cognitive functions, like speech acquisition, dur-
ing the first months and years of life, and that treatment with
Cr before irreversible damage occurs may prevent clinical
symptoms of AGAT and GAMT deficiencies permanently.
As described above, the pre-symptomatic treatment with Cr
in post-natal stages and during the first years of life may also
facilitate the entry of Cr into the brain, at stages where BBB is
not as tightly regulated as in more mature stages, and where
SLC6A8 expression on BBB and BCSFB may still largely
facilitate entry of peripheral Cr into the brain (Braissant et al.
2005; Ireland et al. 2009), in contrast to adulthood (Braissant
et al. 2001b) (Fig. 3). This facilitated entry of Cr into CNS
during the first months and years of life may explain the
success of the lower dose of Cr used (0.1 g/kg/day) to treat
the above-described pre-symptomatic AGAT-deficient patient
(Battini et al. 2006).
Differential developmental importance
of BCSFB and BBB
in exchanges between periphery and CNS
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Fig. 3 Transport of creatine (Cr) at blood-cerebrospinal fluid barrier
(BCSFB) and blood-brain barrier (BBB) in the developmental versus
the adult brain. Fetal and perinatal CNS may predominantly depend on
Cr supply from periphery. This is probably made possible during
development by the high expression of SLC6A8 in CPEC at BCSFB
as well as in fetal ependymal cells and periventricular zone. In contrast,
Cr is supplied to the mature brain by its limited uptake from periphery,
predominantly at BBB, as well as by endogenous synthesis. AGAT:
arginine:glycine amidinotransferase; CNS: central nervous system; Cr:
creatine; CSF: cerebrospinal fluid; GAMT: guanidinoacetate methyl-
transferase; MCEC: microcapillary endothelial cells (BBB); SLC6A8:
Cr transporter
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Change of BBB properties for Cr in brain pathology?
Numerous pathological states of the brain lead to changes or
disturbances of BBB, that can range from adaptation of
transporter expression and activity to a frank rupture of
BBB (Engelhardt and Sorokin 2009; Neuwelt et al. 2011).
This is also true for astrocytes, which are known to become
reactive in many CNS pathological conditions (Zhang and
Barres 2010). In recent years, we have shown that hyper-
ammonemic conditions lead to a secondary Cr deficiency in
brain cells (Bachmann et al. 2004; Braissant et al. 2008;
Braissant 2010b), and that Cr co-treatment exerts neuro-
protective effects against NH4
+ toxicity (Braissant et al.
2002; Braissant 2010a; Cagnon and Braissant 2007). While
SLC6A8 appears absent from astrocytes in normal, physio-
logical conditions, we could show interestingly that NH4
+
exposure induces SLC6A8 expression in these same astro-
cytes (Braissant et al. 2008). Moreover, NH4
+ exposure also
increases both SLC6A8 expression and Cr uptake in MCEC
(Bélanger et al. 2007). Thus, BBB in the hyperammonemic
CNS might be more permeable to Cr than under physiolog-
ical conditions, and supplying oral Cr to hyperammonemic
neonates or infants might likely contribute to protect their
brain development (Braissant 2010a; Braissant 2010b). This
has to be put in perspective of the treatment of other brain
pathologies with Cr. Indeed, Cr administration can exert
protective effects in various neurodegenerative processes,
including Huntington’s and Parkinson’s diseases (Béard
and Braissant 2010; Bender et al. 2006; Hersch et al.
2006; Klein and Ferrante 2007). Creatine was also demon-
strated to exert neuroprotective effects, both in vitro and in
vivo, against anoxic and ischemic damage (Balestrino et al.
2002; Adcock et al. 2002; Lensman et al. 2006) as well as
against traumatic brain injury (Sullivan et al. 2000) and
spinal cord injury (Hausmann et al. 2002).
Creatine derivatives for a better crossing of BBB?
To counteract the limited permeability of BBB for Cr, and in
particular to allow a treatment for SLC6A8-deficient
patients, a lot of work has been performed in order to
develop more lipophilic derivatives of Cr, that would not
need SLC6A8 to be taken up by cells, and that in conse-
quence would cross BBB more easily, possibly by simple
trans-membrane diffusion. While some derivatives (e.g., N-
amidino-piperidine) were harmful, others (e.g., Cr-Mg-
complex acetate, PCr-Mg-complex acetate and Cr ethyl
ester) showed interesting neuroprotective effects in hippo-
campal organotypic cultures (a model with disruption of
BBB) (Perasso et al. 2008; Adriano et al. 2011). PCr-Mg-
complex acetate and another derivative, Cr benzyl ester,
were also demonstrated to cross cell membranes without
the help of the Cr transporter (Lunardi et al. 2006). More
interestingly, PCr-Mg-complex acetate and the very recently
described creatinyl amino acids showed neuroprotective
effects in vivo in rodents, thus suggesting a crossing of
BBB (Burov et al. 2011; Perasso et al. 2009). However so
far, only the Cr derivative Cr ethyl ester has been used
to treat SLC6A8-deficient patients (Fons et al. 2010),
but this compound failed to replenish their brain Cr concen-
tration, as well as to improve their neurological status.
This is probably due to the non-enzymatic conversion of
Cr ethyl ester directly to creatinine, before it reaches CNS
(Giese and Lecher 2009). For the treatment of SLC6A8-
deficient patients, no data are available so far for the
use of other Cr derivatives, in particular those that seem
to cross BBB (PCr-Mg-complex acetate and creatinyl amino
acids).
Models and conclusions
Taken together, (i) the expression patterns of SLC6A8, AGAT
and GAMT at BBB, BCSFB and in the brain, (ii) the func-
tional experiments on Cr and GAA trafficking through BBB
and BCSFB both in vivo and in in vitro models, and (iii) the
clinical characteristics of Cr-deficient patients, lead to the
following models for Cr and GAA transport between periph-
ery and CNS, and for Cr synthesis in CNS (Figs. 1, 2 and 3)
(Béard and Braissant 2010; Braissant et al. 2011; Braissant
and Henry 2008):
In normal conditions, Cr is taken up by CNS from pe-
riphery through SLC6A8 expressed on MCEC at BBB, but
in limited amounts because of the absence of SLC6A8 in the
surrounding astrocytes and the difficult diffusion of Cr
through ECM surrounding BBB. In consequence, the brain
needs its own synthesis to ensure sufficient levels of Cr, and
does so by expressing AGAT and GAMT. No uptake of
GAA from periphery occurs at BBB, except under GAMT
deficiency (and maybe also SLC6A8 deficiency). A net exit
of GAA seems to occur from CSF to blood at BCSFB under
physiological conditions, predominantly through TauT. This
exit of GAA from CSF to blood may be increased under
GAMT deficiency, and uses both TauT and SLC6A8.
A lot of work is still needed to better understand the
transport of Cr, GAA and potentially active Cr derivatives
at BBB and BCSFB, and to allow better treatment for
Cr-deficient patients, in particular those with SLC6A8 defi-
ciency. In particular, a better knowledge of how Cr and GAA
can leave the cells, which so far is very poorly understood
(Figs. 1 and 2), may contribute to more focused and rationale
treatments.
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